Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Infliximab may help prevent post-operative Crohn's disease recurrence

Infliximab may help prevent post-operative Crohn's disease recurrence

February 02, 2009

The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To date, there have been no randomized controlled trials evaluating infliximab for postoperative Crohn's disease prevention.

"Our study provides strong evidence that infliximab is effective at preventing endoscopic, clinical and histological postoperative recurrence of Crohn's disease, and provides a rationale for aggressive postoperative chemoprevention with biologic therapy," said Miguel Regueiro, MD, of the University of Pittsburgh Medical Center. "We are encouraged by our findings, which warrant future study of the duration of post-operative infliximab maintenance and appropriate endoscopic follow up."




Crohn's disease is an inflammation and ulceration process that occurs in the deep layers of the intestinal wall and commonly recurs after intestinal resection. Despite the advent of immunomodulator therapy, approximately 75 percent of Crohn's disease patients require an intestinal resection for complications.

Researchers randomly assigned 24 Crohn's disease patients who had undergone ileocolonic resection to receive intravenous infliximab (5 mg/kg), administered within four weeks of surgery and continued for one year, or placebo. The study's research team elected to use endoscopic recurrence at one year as the primary study endpoint. Secondary endpoints were clinical recurrence and remission and histological recurrence.

At one year, the rate of endoscopic recurrence was significantly lower in the infliximab group (9.1 percent) compared to the placebo group (84.6 percent). There was a non-significant higher proportion of patients in clinical remission in the infliximab group (80 percent) compared to the placebo group (53.8 percent). The histological recurrence rate at one year was significantly lower in the infliximab group (27.3 percent) compared to the placebo group (84.6 percent).

American Gastroenterological Association



Related Infliximab Current Events and Infliximab News Articles Infliximab Current Events and Infliximab News RSS Infliximab Current Events and Infliximab News RSS
Anti-inflammatory drugs may defeat a treatment-resistant type of cancer
Effective drugs for treating a chemotherapy-resistant form of lymphoma might already be on the market according to a study that has pieced together a chemical pathway involved in the disease.

First international guidelines for treatment of psoriatic arthritis
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.

Mayo Clinic collaborates to advance Crohn's treatment
A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment.

'Stuffy nose' mouse: A promise to help treat 31 million with sinusitis
Mice with inflamed nasal tissue being tested at a Johns Hopkins laboratory may be unable to tell if something smells bad or good, but their sensory deficit is nothing to turn up a nose at.

New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).

Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.

New therapeutic targets in the treatment of ulcerative colitis
Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years.

Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients.

Promising drug fails to improve COPD symptoms
A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial.
More Infliximab Current Events and Infliximab News Articles
  Granulomatous infection reports were higher for infliximab than etanercept: etanercept shortage may affect results.(News): An article from: Skin & Allergy News
by Nancy Walsh (Author)

This digital document is an article from Skin & Allergy News, published by International Medical News Group on September 1, 2003. The length of the article is 807 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Granulomatous infection reports were higher for infliximab than etanercept: etanercept shortage may affect results.(News)
Author: Nancy Walsh
Publication: Skin & Allergy News (Magazine/Journal)
Date: September 1, 2003
Publisher: International Medical News Group
Volume: 34 Issue: 9 Page: 6(1)

Distributed by Thomson...

  Infliximab first, not steroids, for best Crohn's treatment.(Digestive Disorders): An article from: Family Practice News
by Mitchel L. Zoler (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on December 1, 2005. The length of the article is 614 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Infliximab first, not steroids, for best Crohn's treatment.(Digestive Disorders)
Author: Mitchel L. Zoler
Publication: Family Practice News (Magazine/Journal)
Date: December 1, 2005
Publisher: International Medical News Group
Volume: 35 Issue: 23 Page: 52(1)

Distributed by Thomson...

  Infliximab and leflunomide show promise for cutaneous sarcoidosis.(Dermatologic Therapy): An article from: Skin & Allergy News
by Damian McNamara (Author)

This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2005. The length of the article is 522 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Infliximab and leflunomide show promise for cutaneous sarcoidosis.(Dermatologic Therapy)
Author: Damian McNamara
Publication: Skin & Allergy News (Magazine/Journal)
Date: June 1, 2005
Publisher: International Medical News Group
Volume: 36 Issue: 6 Page: 28(1)

Distributed by Thomson...

  Acute pulmonary edema during infliximab infusion.(Section on Internal Medicine): An article from: Southern Medical Journal
by Srinivas R. Puli (Author), Martin A. Alpert (Author), Vanaja Puli (Author)

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on October 1, 2004. The length of the article is 489 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Acute pulmonary edema during infliximab infusion.(Section on Internal Medicine)
Author: Srinivas R. Puli
Publication: Southern Medical Journal (Refereed)
Date: October 1, 2004
Publisher: Southern Medical Association
Volume: 97 Issue: 10 Page: S23(1)

Distributed by Thomson...

  Infliximab/MTX combo effective against early RA: major head-to-head trial: findings may alter care for early disease.(News rheumatoid arthritis): An article from: Internal Medicine News
by Diana Mahoney (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on August 1, 2003. The length of the article is 917 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Infliximab/MTX combo effective against early RA: major head-to-head trial: findings may alter care for early disease.(News rheumatoid arthritis)
Author: Diana Mahoney
Publication: Internal Medicine News (Magazine/Journal)
Date: August 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 15 Page: 1(2)

Distributed by Thomson...

  New Arthritis Drugs Fast, Effective.(etanercept and infliximab): An article from: Family Practice News
by Nancy Walsh (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on October 1, 2000. The length of the article is 801 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: New Arthritis Drugs Fast, Effective.(etanercept and infliximab)
Author: Nancy Walsh
Publication: Family Practice News (Magazine/Journal)
Date: October 1, 2000
Publisher: International Medical News Group
Volume: 30 Issue: 19 Page: 14

Distributed by Thomson...

  Infliximab seems effective in treating active ulcerative colitis.(Gastroenterology): An article from: Internal Medicine News
by Kathleen Louden (Author)

This digital document is an article from Internal Medicine News, published by Thomson Gale on October 1, 2005. The length of the article is 595 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Infliximab seems effective in treating active ulcerative colitis.(Gastroenterology)
Author: Kathleen Louden
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2005
Publisher: Thomson Gale
Volume: 38 Issue: 19 Page: 86(1)

Distributed by Thomson...

  Pneumocystis carinii jiroveci pneumonia following infliximab infusion for Crohn disease: emphasis on prophylaxis.(Letter to the editor): An article from: Southern Medical Journal
by Kanan Sharma (Author), Pallavi Rao (Author), Padmini Krishnamurthy (Author), Syed Ahsan Ali (Author), Gregory Beck (Author)

This digital document is an article from Southern Medical Journal, published by Thomson Gale on March 1, 2007. The length of the article is 1001 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Pneumocystis carinii jiroveci pneumonia following infliximab infusion for Crohn disease: emphasis on prophylaxis.(Letter to the editor)
Author: Kanan Sharma
Publication: Southern Medical Journal (Magazine/Journal)
Date: March 1, 2007
Publisher: Thomson Gale
Volume: 100 Issue: 3 Page: 331(2)

Article Type: Letter to the editor

Distributed by Thomson...

  Serial-Dose Infliximab Controls Crohn's Disease.(Remicade): An article from: Internal Medicine News
by Mitchel L. Zoler (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2001. The length of the article is 819 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Serial-Dose Infliximab Controls Crohn's Disease.(Remicade)
Author: Mitchel L. Zoler
Publication: Internal Medicine News (Magazine/Journal)
Date: July 1, 2001
Publisher: International Medical News Group
Volume: 34 Issue: 13 Page: 20

Article Type: Product/Service Evaluation

Distributed by Thomson...

  Infliximab improved psoriasis by 75% in nearly 90% of patients. (Study of 249 Patients).: An article from: Skin & Allergy News
by Betsy Bates (Author)

This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2003. The length of the article is 657 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Infliximab improved psoriasis by 75% in nearly 90% of patients. (Study of 249 Patients).
Author: Betsy Bates
Publication: Skin & Allergy News (Magazine/Journal)
Date: June 1, 2003
Publisher: International Medical News Group
Volume: 34 Issue: 6 Page: 4(1)

Distributed by Thomson...

© 2009 BrightSurf.com